Application | Comment | Organism |
---|---|---|
pharmacology | the enzyme is a target for drug development in human malaria treatment | Homo sapiens |
pharmacology | the enzyme is a target for drug development in human malaria treatment | Plasmodium falciparum |
Cloned (Comment) | Organism |
---|---|
expression of His6-tagged mrk and His6-tagged PK5 in Escherichia coli, co-expression with GST-tagged cyclin-1 | Plasmodium falciparum |
Inhibitors | Comment | Organism | Structure |
---|---|---|---|
(3Z)-3-(2-oxo-2-phenylethylidene)-1,3-dihydro-2H-indol-2-one | IC50 for CDK1 is above 0.016 mM | Homo sapiens | |
(3Z)-3-(2-oxo-2-phenylethylidene)-1,3-dihydro-2H-indol-2-one | IC50 for mrk is 0.0040 mM, and for PK5 0.15 mM, only weak inhibition of parasite strains D6 and W2 growth | Plasmodium falciparum | |
(3Z)-3-[2-(4-bromophenyl)-2-oxoethylidene]-1,3-dihydro-2H-indol-2-one | IC50 for CDK1 is 0.012 mM | Homo sapiens | |
(3Z)-3-[2-(4-bromophenyl)-2-oxoethylidene]-1,3-dihydro-2H-indol-2-one | IC50 for mrk is 0.0035 mM, and for PK5 0.13 mM, only weak inhibition of parasite strains D6 and W2 growth | Plasmodium falciparum | |
(3Z)-5-bromo-3-(2-oxo-2-phenylethylidene)-1,3-dihydro-2H-indol-2-one | IC50 for CDK1 is 0.030 mM | Homo sapiens | |
(3Z)-5-bromo-3-(2-oxo-2-phenylethylidene)-1,3-dihydro-2H-indol-2-one | IC50 for mrk is 0.0031 mM, and for PK5 0.12 mM, only weak inhibition of parasite strains D6 and W2 growth | Plasmodium falciparum | |
(3Z)-5-bromo-3-[2-(4-fluorophenyl)-2-oxoethylidene]-1,3-dihydro-2H-indol-2-one | IC50 for CDK1 is 0.029 mM | Homo sapiens | |
(3Z)-5-bromo-3-[2-(4-fluorophenyl)-2-oxoethylidene]-1,3-dihydro-2H-indol-2-one | IC50 for mrk is 0.0014 mM, and for PK5 0.19 mM, only weak inhibition of parasite strains D6 and W2 growth | Plasmodium falciparum | |
(3Z)-5-bromo-3-[2-(4-methylphenyl)-2-oxoethylidene]-1,3-dihydro-2H-indol-2-one | IC50 for CDK1 is 0.029 mM | Homo sapiens | |
(3Z)-5-bromo-3-[2-(4-methylphenyl)-2-oxoethylidene]-1,3-dihydro-2H-indol-2-one | IC50 for mrk is 0.0029 mM, and for PK5 0.12 mM, only weak inhibition of parasite strains D6 and W2 growth | Plasmodium falciparum | |
additional information | molecular modeling of inhibitor-enzyme interactions | Plasmodium falciparum | |
oxindole-based compounds | highly selective for mrk, IC50 of mrk is 0.0015 mM, low cross-reactivity with PK5 and human CDK1 | Plasmodium falciparum |
Metals/Ions | Comment | Organism | Structure |
---|---|---|---|
Mn2+ | - |
Homo sapiens | |
Mn2+ | - |
Plasmodium falciparum |
Organism | UniProt | Comment | Textmining |
---|---|---|---|
Homo sapiens | - |
- |
- |
Plasmodium falciparum | - |
strains D6 and W2 | - |
Purification (Comment) | Organism |
---|---|
recombinant His6-tagged mrk, His6-tagged PK5, and GST-tagged cyclin-1 from Escherichia coli | Plasmodium falciparum |
Reaction | Comment | Organism | Reaction ID |
---|---|---|---|
ATP + a [protein]-(L-serine/L-threonine) = ADP + a [protein]-(L-serine/L-threonine) phosphate | active site amino acid sequences of PK5 and mrk | Plasmodium falciparum |
Substrates | Comment Substrates | Organism | Products | Comment (Products) | Rev. | Reac. |
---|---|---|---|---|---|---|
ATP + C-terminal domain of RNA polymerase II | - |
Homo sapiens | ADP + phosphorylated C-terminal domain of RNA polymerase II | - |
? | |
ATP + C-terminal domain of RNA polymerase II | - |
Plasmodium falciparum | ADP + phosphorylated C-terminal domain of RNA polymerase II | - |
? |
Synonyms | Comment | Organism |
---|---|---|
CDK | - |
Plasmodium falciparum |
Cdk1 | - |
Homo sapiens |
mrk | - |
Plasmodium falciparum |
PK5 | - |
Plasmodium falciparum |
Temperature Optimum [°C] | Temperature Optimum Maximum [°C] | Comment | Organism |
---|---|---|---|
30 | - |
assay at | Homo sapiens |
30 | - |
assay at | Plasmodium falciparum |
pH Optimum Minimum | pH Optimum Maximum | Comment | Organism |
---|---|---|---|
7.5 | - |
assay at | Homo sapiens |
7.5 | - |
assay at | Plasmodium falciparum |
Cofactor | Comment | Organism | Structure |
---|---|---|---|
ATP | - |
Homo sapiens | |
ATP | - |
Plasmodium falciparum | |
cyclin-1 | regulatory subunit | Plasmodium falciparum |
IC50 Value | IC50 Value Maximum | Comment | Organism | Inhibitor | Structure |
---|---|---|---|---|---|
0.0014 | - |
IC50 for mrk is 0.0014 mM, and for PK5 0.19 mM, only weak inhibition of parasite strains D6 and W2 growth | Plasmodium falciparum | (3Z)-5-bromo-3-[2-(4-fluorophenyl)-2-oxoethylidene]-1,3-dihydro-2H-indol-2-one | |
0.0015 | - |
highly selective for mrk, IC50 of mrk is 0.0015 mM, low cross-reactivity with PK5 and human CDK1 | Plasmodium falciparum | oxindole-based compounds | |
0.0029 | - |
IC50 for mrk is 0.0029 mM, and for PK5 0.12 mM, only weak inhibition of parasite strains D6 and W2 growth | Plasmodium falciparum | (3Z)-5-bromo-3-[2-(4-methylphenyl)-2-oxoethylidene]-1,3-dihydro-2H-indol-2-one | |
0.0031 | - |
IC50 for mrk is 0.0031 mM, and for PK5 0.12 mM, only weak inhibition of parasite strains D6 and W2 growth | Plasmodium falciparum | (3Z)-5-bromo-3-(2-oxo-2-phenylethylidene)-1,3-dihydro-2H-indol-2-one | |
0.0035 | - |
IC50 for mrk is 0.0035 mM, and for PK5 0.13 mM, only weak inhibition of parasite strains D6 and W2 growth | Plasmodium falciparum | (3Z)-3-[2-(4-bromophenyl)-2-oxoethylidene]-1,3-dihydro-2H-indol-2-one | |
0.004 | - |
IC50 for mrk is 0.0040 mM, and for PK5 0.15 mM, only weak inhibition of parasite strains D6 and W2 growth | Plasmodium falciparum | (3Z)-3-(2-oxo-2-phenylethylidene)-1,3-dihydro-2H-indol-2-one | |
0.012 | - |
IC50 for CDK1 is 0.012 mM | Homo sapiens | (3Z)-3-[2-(4-bromophenyl)-2-oxoethylidene]-1,3-dihydro-2H-indol-2-one | |
0.016 | - |
IC50 for CDK1 is above 0.016 mM | Homo sapiens | (3Z)-3-(2-oxo-2-phenylethylidene)-1,3-dihydro-2H-indol-2-one | |
0.029 | - |
IC50 for CDK1 is 0.029 mM | Homo sapiens | (3Z)-5-bromo-3-[2-(4-methylphenyl)-2-oxoethylidene]-1,3-dihydro-2H-indol-2-one | |
0.029 | - |
IC50 for CDK1 is 0.029 mM | Homo sapiens | (3Z)-5-bromo-3-[2-(4-fluorophenyl)-2-oxoethylidene]-1,3-dihydro-2H-indol-2-one | |
0.03 | - |
IC50 for CDK1 is 0.030 mM | Homo sapiens | (3Z)-5-bromo-3-(2-oxo-2-phenylethylidene)-1,3-dihydro-2H-indol-2-one |